Repare Therapeutics Ownership
| RPTX Stock | USD 3.32 0.17 5.40% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 42.4 M | Current Value 42.5 M | Avarage Shares Outstanding 35.7 M | Quarterly Volatility 9.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Repare |
Repare Stock Ownership Analysis
About 84.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Repare Therapeutics recorded a loss per share of 1.99. The entity had not issued any dividends in recent years. Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company was incorporated in 2016 and is headquartered in Montreal, Canada. Repare Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people. To find out more about Repare Therapeutics contact Lloyd Segal at 857 412 7018 or learn more at https://www.reparerx.com.Besides selling stocks to institutional investors, Repare Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Repare Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Repare Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Repare Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Repare Therapeutics Insider Trades History
Less than 1% of Repare Therapeutics are currently held by insiders. Unlike Repare Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Repare Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Repare Therapeutics' insider trades
Repare Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Repare Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repare Therapeutics backward and forwards among themselves. Repare Therapeutics' institutional investor refers to the entity that pools money to purchase Repare Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nikko Asset Management Americas Inc | 2024-06-30 | 277.2 K | Millennium Management Llc | 2024-06-30 | 249.5 K | Sumitomo Mitsui Trust Group Inc | 2024-09-30 | 249.2 K | Gsa Capital Partners Llp | 2024-09-30 | 240.5 K | Affinity Asset Advisors, Llc | 2024-09-30 | 173.4 K | D. E. Shaw & Co Lp | 2024-09-30 | 149.7 K | Squarepoint Ops Llc | 2024-06-30 | 143 K | Blackrock Inc | 2024-06-30 | 141.8 K | Bank Of Montreal | 2024-06-30 | 110.9 K | Bvf Inc | 2024-09-30 | 10.3 M | Blue Owl Capital Holdings Lp | 2024-09-30 | 3.4 M |
Repare Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repare Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repare Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repare Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repare Therapeutics Outstanding Bonds
Repare Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Repare Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Repare bonds can be classified according to their maturity, which is the date when Repare Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Repare Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 20th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.